Indole-3-carbinol as a chemoprotective agent in breast and prostate cancer

In Vivo

Volumn 22, Issue 4, 2008, Pages 441-446

  Bradlow, H Leon ^a,b  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Activity; Diindolylmethane (DIM); Indole 3 carbinol (I3C); Pro drug; Review

Indexed keywords

2 HYDROXYESTRONE; 3 INDOLEMETHANOL; 4 HYDROXYESTROGEN; 4 HYDROXYESTRONE; CARCINOGEN; CYTOCHROME P450 1A2; DIINDOLYLMETHANE; INDOLE DERIVATIVE; ANTINEOPLASTIC AGENT; INDOLE-3-CARBINOL;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PREVENTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG POTENCY; DRUG TRANSFORMATION; ENZYME INDUCTION; HUMAN; HYDROXYLATION; NONHUMAN; PROSTATE CANCER; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX DYSPLASIA; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; CHEMOPROPHYLAXIS; FEMALE; GENE EXPRESSION REGULATION; MALE; ORAL DRUG ADMINISTRATION; PROSTATE TUMOR; RAT; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMOPREVENTION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RATS;

EID: 48349127559     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Loub WD, Wattenberg LW and Davis DW: Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J Natl Cancer Inst 54: 985-988, 1975.
2. Gao X, Petroff BK, Oluola O, Georg G, Terranova PF and Rozman KK: Endocrine disruption by indole-3-carbinol and tamoxifen: blockage of ovulation. Toxicol Appl Pharmacol 183: 179-188, 2002.
3. Yoshida M, Katashima S, Ando J, Tanaka T, Uematsu F, Nakae D and Maekawa A: Dietary indole-3-carbinol promotes endometrial adenocarcinoma development in rats initiated with N-ethyl-N′-nitro-N-nitrosoguanidine, with induction of cytochrome P450s in the liver and consequent modulation of estrogen metabolism. Carcinogenesis 25: 2257-2264, 2004.
4. Dashwood RH: Indole-3-carbinol: anticarcinogen or tumor promoter in brassica vegetables? Chem Biol Interact 110: 1-5, 1998.
5. De Kruif CA, Marsman JW, Venrkamp JC and Falke J: Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. Chem Biol Interact 80: 303-315, 1991.
6. Bradlow H, Michnovicz JJ, Telang N and Osborne MP: Effect of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12: 1571-1574, 1991.
7. Grubbs CJ, Steele VE, Casebolt T, Julianna MM, Eto I, Whitaker LM, Dragnev KH, Keloff GJ and Lubet RL: Chemoprevention of chemically induced mammary tumors. Anticancer Res 15: 709-716, 1995.
8. Kojima T, Tanaka T and Mori H: Chemoprevention of spontaneous endometrial cancer in female Donryku rats by dietary indole-3-carbinol. Cancer Res 5: 1446-1449, 1994.
9. Souli E, Machluf M, Morgenstern A, Sabo E and Yannai S: Indole-3-carbinol (I3C) exhibits inhibitory and preventive effects on prostate tumors in mice. Food Chem Toxicol 46: 815-828, 2008.
10. Telang NT, Kurihara T, Wong GY, Bradlow HL and Osborne MP: Preneoplastic transformation in mouse mammary tissue: identification and validation of intermediate biomarkers for chemoprevention. Anticancer Res 11: 1021-1027, 1991.
11. Michnovicz JJ and Bradlow HL: Induction of estradiol metabolism by dietary indole-3-carbinol in humans. J Natl Cancer Inst 50: 947-950, 1990.
12. Chang X, Tou JC, Hong C, Kim HA, Riby JE, Firestone GL and Bjeldane LF: 3, 3′-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 26: 771-778, 2005.
13. Nachshon-Kedmi M, Fares FA and Yannai S: Therapeutic activity of 3,3′-diindolylmethane on prostate cancer in an in vivo model. Prostate 61: 153-160, 2004.
14. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S and Sarkar FH: Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 61: 10064-10072, 2006.
15. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL and Bjeldanes LF: Pilot study: effect of 3,3-pm-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer 50: 161-167, 2004.
16. Preobrazhenskaya MN, Bukhman VM, Korolev AM and Efimov SA: Ascorbigen and other indole-derived compounds from Brassica vegetables and their analogs as anticarcinogenic and immunomodulating agents. Pharmacol Ther 60: 301-313, 1993.
17. Chang YC, Riby J, Chang GH, Peng BC, Firestone G and Bjeldanes LF: Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3′-diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Biochem Pharmacol 58: 825-834, 1999.
18. Zeligs MA and Bradlow HL: Diindolylmethane (DIM), formed from indole-3-carbinol (I3C), is the dominant anti-proliferative indole in cell culture media after adding I3C. 97th AACR meeting Abst. 5597 2004.
19. Anderton MJ, Manson MM, Verschoyle RD, Gescher A, Lamb JH, Farmer PB, Steward WP and Williams M: Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin Cancer Res 10: 5233-5241, 2004.
20. Howells LM, Moiseeva EP, Neal CP, Foreman BE, Andreadi CK, Sun YY, Hudson E and Manson MM: Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin 28: 1274-1304, 2007.
21. Reed GA, Arneson DW, Putnam WC, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA and Hurwitz A: single- and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3′-diindolylmethane. Cancer Epidemiol Biomarkers Prev 15: 2477-2481, 2006.
22. Stresser DM, Williams DE, Griffin DA and Bailey GS: Mechanisms of tumor modulation by indole-3-carbinol. Disposition and excretion in male Fischer 344 rats. Drug Metab Dispos 23: 965-975, 1975.
23. Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux EJ, Tucker A, Turbat-Herrera EA and Matis JM: Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 78: 123-129, 2000.
24. Jellinck PH, Forkert PG, Riddick DS, Okey AB, Michnovicz JJ and Bradlow HL: Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem Pharmacol 45: 1129-1136, 1993.
25. Garikapati VP, Ashok BT, Chen YG, Mittelman A, Iatropoulos M and Tiwari RK: Anti-carcinogenic and anti-metastatic properties of indole-3-carbinol in prostate cancer. Oncol Rep 13: 89-93, 2005.
26. Staub RE, Feng C, Onisko B, Bailey GS, Firestone GL and Bjeldanes L: Fate of indole-3-carbinol in cultured human breast tumor cells. Chem Res Toxicol 15: 101-109, 2002.
27. Parkin DR and Malejka-Giganti D: Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3′-diindolylmethane and its parent compound indole-3-carbinol. Cancer Detect Prev 28: 72-79, 2004.
28. Garikapati VP, Ashok BT, Tadi K, Mittelman A and Tiwari RK: Synthetic dimer of indole-3-carbinol: second generation diet derived anti-cancer agent in hormone sensitive prostate cancer. Prostate 66: 453-462, 2006.
29. Chen DZ, Qi M, Auborn KJ and Carter TH: Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J Nutr 131: 3294-3302, 2001.
30. Wang TT, Milner MJ, Milner JA and Kim YS: Estrogen receptor alpha as a target for indole-3-carbinol. J Nutr Biochem 17: 659-664, 2006.
31. Crowell JA, Page JG, Levine BS, Tomlinson MJ and Hebert CD: Indole-3-carbinol, but not its major digestive product 3,3′-diindolylmethane, induces reversible hepatocyte hypertrophy and cytochromes P450. Toxicol Appl Pharmacol 211: 115-123, 2006.
32. Leibelt DA, Hedstrom OR, Fischer KA, Pereira CB and Williams DE: Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3′-diindolylmethane in Sprague-Dawley rats. Toxicol Sci 74: 10-21, 2004.
33. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I and Osborne MP: Catechol estrogen production in rat microsomes after treatment with indole-3-carbinol, Ascorbigen, or beta-naphthaflavone: a comparison of stable isotope dilution gas chromatography-mass spectrometry and radiometric methods. Steroids 59: 318-323, 1994.
34. Horn TL, Reichert MA, Bliss RL and Malejka-Giganti D: Modulations of P450 mRNA in liver and mammary gland and P450 activities and metabolism of estrogen in liver by treatment of rats with indole-3-carbinol. Biochem Pharmacol 64: 393-404, 2002.
35. Michnovicz JJ, Adlercreutz H and Bradlow HL: Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst 89: 718-723, 1997.
36. Singh S, Chakravarti D, Edney JA, Hollins RR, Johnson PJ, West WW, Higginbotham SM, Cavalieri EL and Rogan EG: Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma. Oncol Rep 14: 1091-1096, 2005.
37. Berstein LM, Tsyrlina EV, Kolesnik OS, Gamajunova VB and Adlercreutz H: Catechol estrogens excretion in smoking and non-smoking postmenopausal women receiving estrogen replacement therapy. J Steroid Biochem Mol Biol. 72: 143-147, 2000.
38. Saintot M, Malaveille C, Hautefeuille A and Gerber M: Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-O-methyl-transferase and tobacco exposure in breast cancer risk, Int J Cancer 107: 652-657, 2003.
39. Yan YE, Wang H, Wang T and Zeng HG: Indole-3-carbinol alters placental cytochrome P450 1A1 and P-glycoprotein levels in rats: a potential role in intensifying fetal intrauterine growth-retardation produced by tobacco smoke. Exp Toxicol Pathol 58: 39-47, 2006.
40. Cavalieri E and Rogan E: Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture Estrogens and Cancer. Bradlow HL and Carruba G (eds.). Ann NY Acad Sci 1089: 286-301, 2006.
41. Donald S, Verschoyle RD, Greaves P, Colombo T, Zucchetti M, Falcioni C, Zaffaroni M, D'Incalci M, Manson MM, Jimeno J, Steward WP and Gescher AJ: Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. Int J Cancer 111: 961-967, 2004.
42. Rogan EG: The natural chemopreventive compound indole-3-carbinol: state of the science. In Vivo 20: 221-228, 2006.
43. Hestermann EV and Brown M: Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cellular Biol 23: 7920-7925, 2003.
44. Zeligs MA, Fulfs JC, Peterson R, Wilson SM, McIntyre L, Sepkovic DW and Bradlow HL: In vivo, uterine-protective activity of absorption-enhanced diindolylmethane: Animal and preliminary human use in combination with Tamoxifen. Proc Am Assoc Cancer Res 44: 1268, (abstract #6347) 2003.
45. Reed GA, Peterson KS, Smith HJ, Gray JC, Sullivan DK, Mayo MS, Crowell JA and Hurwitz AA: Phase I study of indole-3-carbinol in women: tolerability and effects. Cancer Epidemiol Biomarkers Prev 14: 1953-1960, 2005.
46. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M and Saleh TM: Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 15: 551-558, 2006.
47. Zeligs MA, Brownstone PK, Sharp ME, Westerlind K, Wilson SM and Johs S: Managing cyclical mastalgia with absorbable DIM: A randomized, placebo-controlled trial. JANA 7: 5-14, 2005.